Ketamine: a paradigm shift for depression research and treatment
John H. Krystal, Chadi G. Abdallah, Gerard Sanacora, Dennis S. Charney, Ronald S. Duman
Neuron March 1, 2019 DOI: 10.1016/j.neuron.2019.02.005 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Citations | 443 |
| Key findings | Ketamine is a rapid-acting antidepressant effective for treatment-resistant mood disorders, and its mechanisms are overturning established views on the neurobiology of depression. |
Abstract
Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy shed new light on the mechanisms underlying antidepressant efficacy. The rapid, profound, and sustainable antidepressant effects of ketamine seem poised to transform the treatment of depression, while mechanisms through which it may work are overturning the received wisdom regarding the underlying neurobiology.